USFDA completes GMP Inspection at Lupin’s API manufacturing facility in Visakhapatnam

11 Mar 2023 Evaluate

The United States Food and Drug Administration (USFDA) has completed a Pre-Approval and GMP Inspection at Lupin’s API manufacturing facility located in Visakhapatnam (Vizag), India. The inspection was conducted from March 6, 2023 to March 10, 2023 and concluded with no observations. This accomplishment is a testament to the company’s commitment to upholding global quality standards across all its manufacturing sites, and to provide quality affordable healthcare for all. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×